Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dexmedetomidine** is a selective central alpha-2 adrenergic receptor agonist sedative developed by Orion. It reduces sympathetic noradrenergic signaling, producing cooperative sedation, anxiolysis, and analgesic-sparing effects while generally preserving respiratory drive. In the Jincheng General Hospital study, intravenous dexmedetomidine is being evaluated with lower-limb warming blankets for prevention of postoperative delirium and postoperative chills in elderly patients undergoing posterior spinal surgery under general anesthesia. This perioperative preventive use is investigational and distinct from the drug's established sedation uses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexmedetomidine (Orion Corporation).